New Zealand
· Delayed Price · Currency is NZD Pacific Edge Company Description
Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally.
It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.
It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect, which enables the risk stratification of patients with haematuria; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence.
In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma.
Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
| Country | New Zealand |
| Founded | 2001 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Peter Meintjes |
Contact Details
Address: Centre for Innovation Dunedin, 9016 New Zealand | |
| Phone | 64 3 577 6733 |
| Website | pacificedgedx.com |
Stock Details
| Ticker Symbol | PEB |
| Exchange | New Zealand Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | NZD |
| ISIN Number | NZPEBE0002S1 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Peter Meintjes | Chief Executive Officer |
| Grant Gibson | Chief Financial Officer |
| Darrell Morgan | Chief Operating Officer |